Display options
Share it on

Nutr Metab (Lond). 2013 Jan 22;10(1):12. doi: 10.1186/1743-7075-10-12.

Effects of orally applied butyrate bolus on histone acetylation and cytochrome P450 enzyme activity in the liver of chicken - a randomized controlled trial.

Nutrition & metabolism

Gábor Mátis, Zsuzsanna Neogrády, György Csikó, Anna Kulcsár, Akos Kenéz, Korinna Huber

Affiliations

  1. Department of Physiology, University of Veterinary Medicine, Bischofsholer Damm 15/102, D-30173, Hannover, Germany. [email protected].

PMID: 23336999 PMCID: PMC3561214 DOI: 10.1186/1743-7075-10-12

Abstract

BACKGROUND: Butyrate is known as histone deacetylase inhibitor, inducing histone hyperacetylation in vitro and playing a predominant role in the epigenetic regulation of gene expression and cell function. We hypothesized that butyrate, endogenously produced by intestinal microbial fermentation or applied as a nutritional supplement, might cause similar in vivo modifications in the chromatin structure of the hepatocytes, influencing the expression of certain genes and therefore modifying the activity of hepatic microsomal drug-metabolizing cytochrome P450 (CYP) enzymes.

METHODS: An animal study was carried out in chicken as a model to investigate the molecular mechanisms of butyrate's epigenetic actions in the liver. Broiler chicks in the early post-hatch period were treated once daily with orally administered bolus of butyrate following overnight starvation with two different doses (0.25 or 1.25 g/kg body weight per day) for five days. After slaughtering, cell nucleus and microsomal fractions were separated by differential centrifugation from the livers. Histones were isolated from cell nuclei and acetylation of hepatic core histones was screened by western blotting. The activity of CYP2H and CYP3A37, enzymes involved in biotransformation in chicken, was detected by aminopyrine N-demethylation and aniline-hydroxylation assays from the microsomal suspensions.

RESULTS: Orally added butyrate, applied in bolus, had a remarkable impact on nucleosome structure of hepatocytes: independently of the dose, butyrate caused hyperacetylation of histone H2A, but no changes were monitored in the acetylation state of H2B. Intensive hyperacetylation of H3 was induced by the higher administered dose, while the lower dose tended to increase acetylation ratio of H4. In spite of the observed modification in histone acetylation, no significant changes were observed in the hepatic microsomal CYP2H and CYP3A37 activity.

CONCLUSION: Orally added butyrate in bolus could cause in vivo hyperacetylation of the hepatic core histones, providing modifications in the epigenetic regulation of cell function. However, these changes did not result in alteration of drug-metabolizing hepatic CYP2H and CYP3A37 enzymes, so there might be no relevant pharmacoepigenetic influences of oral application of butyrate under physiological conditions.

References

  1. J Biol Chem. 2006 Jan 6;281(1):559-68 - PubMed
  2. J Mol Biol. 2005 Feb 11;346(1):135-46 - PubMed
  3. Poult Sci. 2009 May;88(5):943-8 - PubMed
  4. Mol Pharmacol. 2009 May;75(5):1171-9 - PubMed
  5. Cell. 1978 May;14(1):105-13 - PubMed
  6. J Biol Chem. 1974 Oct 10;249(19):6302-10 - PubMed
  7. Int J Antimicrob Agents. 2007 Aug;30(2):101-7 - PubMed
  8. Poult Sci. 2003 Apr;82(4):632-9 - PubMed
  9. J Genet Genomics. 2012 Aug 20;39(8):375-84 - PubMed
  10. Biochem Pharmacol. 1982 Sep 15;31(18):3002-5 - PubMed
  11. Clin Pharmacol Ther. 1990 Nov;48(5):490-5 - PubMed
  12. Biomed Pharmacother. 2010 Dec;64(10):733-40 - PubMed
  13. Gut. 1993 Mar;34(3):386-91 - PubMed
  14. Biochemistry. 2009 Jun 9;48(22):5007-17 - PubMed
  15. Adv Exp Med Biol. 1997;427:123-34 - PubMed
  16. Mol Cell Proteomics. 2002 Jul;1(7):500-8 - PubMed
  17. Adv Genet. 2010;70:341-86 - PubMed
  18. J Nutr. 1986 Jan;116(1):77-86 - PubMed
  19. Carcinogenesis. 2007 Feb;28(2):240-5 - PubMed
  20. Genome Res. 2007 Jun;17(6):708-19 - PubMed
  21. Acta Vet Hung. 2013 Dec;61(4):477-90 - PubMed
  22. Acta Vet Hung. 1990;38(1-2):3-17 - PubMed
  23. Biochem J. 1953 Oct;55(3):416-21 - PubMed
  24. Pharmacol Rep. 2011;63(2):293-304 - PubMed
  25. J Biol Chem. 2010 Feb 26;285(9):6750-60 - PubMed
  26. Physiol Rev. 1990 Apr;70(2):567-90 - PubMed
  27. Nutr Metab (Lond). 2009 Mar 07;6:11 - PubMed
  28. Clin Nutr. 2009 Dec;28(6):657-61 - PubMed
  29. J Nutr. 2003 Jul;133(7 Suppl):2485S-2493S - PubMed
  30. Nutr Metab (Lond). 2012 Mar 27;9(1):23 - PubMed
  31. Cancer Res. 1997 Sep 1;57(17):3697-707 - PubMed
  32. Anal Biochem. 2002 Jul 15;306(2):259-69 - PubMed
  33. BMC Genomics. 2006 Jul 19;7:181 - PubMed
  34. Funct Integr Genomics. 2012 Mar;12(1):119-30 - PubMed
  35. JPEN J Parenter Enteral Nutr. 2008 Jan-Feb;32(1):51-6 - PubMed
  36. BMC Physiol. 2007 Aug 28;7:8 - PubMed
  37. J Nutr. 2001 Jul;131(7):1986-92 - PubMed
  38. Nutr Metab (Lond). 2011 Jun 15;8(1):38 - PubMed
  39. Int J Food Microbiol. 2010 Jun 15;140(2-3):93-101 - PubMed
  40. Gastroenterology. 1982 Aug;83(2):424-9 - PubMed
  41. Nutr Res Rev. 2010 Dec;23(2):366-84 - PubMed

Publication Types